As of 2026-09-18, the EV/EBITDA ratio of Reata Pharmaceuticals Inc (RETA) is -15.37. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RETA's latest enterprise value is 5,813.45 mil USD. RETA's TTM EBITDA according to its financial statements is -378.12 mil USD. Dividing these 2 quantities gives us the above RETA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.9x - 16.4x | 11.9x |
| Forward P/E multiples | 11.9x - 15.8x | 14.2x |
| Fair Price | (135.14) - (179.05) | (147.64) |
| Upside | -178.4% - -203.9% | -185.7% |
| Date | EV/EBITDA |